Global Retirement Partners LLC lifted its holdings in shares of Repligen Corporation (NASDAQ:RGEN – Free Report) by 70.9% in the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 8,202 shares of the biotechnology company’s stock after buying an additional 3,403 shares during the period. Global Retirement Partners LLC’s holdings in Repligen were worth $1,577,000 at the end of the most recent reporting period.
Several other large investors have also recently added to or reduced their stakes in RGEN. United Capital Financial Advisors LLC bought a new position in Repligen in the 2nd quarter worth approximately $380,756,000. Wasatch Advisors LP boosted its position in Repligen by 27.9% during the 2nd quarter. Wasatch Advisors LP now owns 1,590,251 shares of the biotechnology company’s stock worth $216,974,000 after acquiring an additional 346,720 shares during the period. Maverick Capital Ltd. acquired a new position in Repligen during the 1st quarter worth $178,946,000. William Blair Investment Management LLC grew its stake in shares of Repligen by 57.7% in the third quarter. William Blair Investment Management LLC now owns 1,243,415 shares of the biotechnology company’s stock worth $239,022,000 after purchasing an additional 454,844 shares in the last quarter. Finally, Congress Asset Management Co. increased its holdings in shares of Repligen by 0.9% during the third quarter. Congress Asset Management Co. now owns 1,020,907 shares of the biotechnology company’s stock valued at $196,249,000 after purchasing an additional 8,681 shares during the period. 97.64% of the stock is owned by institutional investors and hedge funds.
Wall Street Analysts Forecast Growth
RGEN has been the subject of a number of research analyst reports. Weiss Ratings downgraded Repligen from a “hold (c)” rating to a “sell (d+)” rating in a research report on Monday, November 2nd. Barclays boosted their price objective on Repligen from $175.00 to $225.00 and gave the stock an “overweight” rating in a research note on Wednesday, October 7th. Canaccord Genuity Group upped their price objective on Repligen from $145.00 to $180.00 and gave the company a “hold” rating in a report on Monday, October 19th. JPMorgan Chase & Co. raised their target price on Repligen from $165.00 to $175.00 and gave the company an “overweight” rating in a research note on Wednesday, July 29th. Finally, Wells Fargo & Company lifted their target price on Repligen from $180.00 to $185.00 and gave the stock an “overweight” rating in a report on Thursday, July 30th. Two research analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Repligen has a consensus rating of “Moderate Buy” and an average price target of $178.57.
Repligen Price Performance
RGEN opened at $163.81 on Friday. The stock has a fifty day moving average of $177.16 and a 200-day moving average of $145.99. The firm has a market capitalization of $10.47 billion, a P/E ratio of -780.01, a PEG ratio of 2.81 and a beta of 1.11. Repligen Corporation has a 12-month low of $100.99 and a 12-month high of $198.87. The company has a quick ratio of 8.43, a current ratio of 9.88 and a debt-to-equity ratio of 0.27.
Repligen (NASDAQ:RGEN – Get Free Report) last issued its quarterly earnings results on Tuesday, October 27th. The biotechnology company reported $0.53 earnings per share for the quarter, beating analysts’ consensus estimates of $0.46 by $0.07. The business had revenue of $209.31 million for the quarter, compared to the consensus estimate of $206.70 million. Repligen had a positive return on equity of 5.49% and a negative net margin of 1.47%. Repligen’s revenue for the quarter was up 10.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.46 earnings per share. Equities analysts forecast that Repligen Corporation will post 2.07 EPS for the current fiscal year.
About Repligen
Repligen is a life sciences company that develops and supplies technologies used in the manufacture of biologic medicines. Its products support biopharmaceutical companies and contract manufacturers in producing treatments such as monoclonal antibodies, vaccines and gene therapies. The company’s offerings span several stages of bioprocessing, including filtration, chromatography, fluid management and process analytics. Its products include filtration systems and single-use components, chromatography solutions and instruments that help monitor and control manufacturing processes.
Further Reading
- Five stocks we like better than Repligen
- ZIM Just Posted Huge Profits, But Its $35 Buyout Is Still in Limbo
- Owens Corning’s Stock Slump May Have a Silver Lining for Dividend Investors
- The Patchpocalypse Could Be a Big Opportunity for These 2 Cybersecurity Stocks
- Anthropic’s Record IPO Could Ease a Major Concern for Broadcom Investors
Want to see what other hedge funds are holding RGEN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Repligen Corporation (NASDAQ:RGEN – Free Report).
Receive News & Ratings for Repligen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen and related companies with MarketBeat.com's FREE daily email newsletter.
